Chongqing Genrix Biopharmaceutical (SHA:688443) said its self-developed selikizumab injection has been included in China's 2025 national reimbursement drug list.
The drug treats metastatic moderate to severe plaque psoriasis and ankylosing spondylitis, according to a Monday filing with the Shanghai bourse.
The inclusion will take effect on Jan. 1, 2026.
Shares of the pharmaceutical company were down 1% Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments